Invasive Mold Infections After Chimeric Antigen Receptor-Modified T-Cell Therapy: A Case Series, Review of the Literature, and Implications for Prophylaxis

Ghady Haidar; Kathleen Dorritie; Rafic Farah; Tatiana Bogdanovich; M Hong Nguyen; Palash Samanta

doi:10.1093/cid/ciz1127

Invasive Mold Infections After Chimeric Antigen Receptor-Modified T-Cell Therapy: A Case Series, Review of the Literature, and Implications for Prophylaxis

Clin Infect Dis. 2020 Jul 27;71(3):672-676. doi: 10.1093/cid/ciz1127.

Authors

Ghady Haidar^{1

2}, Kathleen Dorritie^{1

3}, Rafic Farah³, Tatiana Bogdanovich², M Hong Nguyen^{1

2}, Palash Samanta²

Affiliations

¹ University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
² Division of Infectious Diseases, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
³ Division of Hematology and Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.

PMID: 31756246
DOI: 10.1093/cid/ciz1127

Abstract

Data on invasive mold infections (IMIs) after chimeric antigen receptor-modified T-cell (CAR-T-cell) therapy are limited. We describe 2 patients with post-CAR-T-cell IMI (Fusarium, Mucorales) and review the published literature. We propose strategies to prevent IMIs in patients, based on the IMI rate and presence of neutropenia or steroid use.

Keywords: CAR-T-cell; fungal infections; neutropenia; prophylaxis; steroids.

Publication types

Review

MeSH terms

Cell- and Tissue-Based Therapy
Humans
Immunotherapy, Adoptive
Mucorales*
Neutropenia*
Receptors, Chimeric Antigen*

Substances

Receptors, Chimeric Antigen